Pharma
Oral vs Injectable GLP-1s: The 2026 Weight Loss Drug Shift

Oral vs Injectable GLP-1s: The 2026 Weight Loss Drug Shift

The arrival of two approved oral GLP-1 weight loss therapies in the space of four months has fundamentally redrawn the obesity treatment landscape in 2026. For years, the question of whether a daily pill could ever match the efficacy of a weekly injection was largely...

read more
Why Biopharma Must Invest in Novel Targets

Why Biopharma Must Invest in Novel Targets

Drug development continues to concentrate on a small set of well-known targets, creating a crowded landscape where many companies pursue similar pathways. While research into novel mechanisms continues, familiar targets often take priority, reflecting a cautious...

read more
From Flower to Pharmacy: The Science Behind Manuka Honey

From Flower to Pharmacy: The Science Behind Manuka Honey

Not all honey is created equal. That statement, once dismissed as marketing language, is now well-supported by peer-reviewed chemistry. Manuka honey is produced by bees foraging on Leptospermum scoparium, a flowering shrub native to New Zealand and south-eastern...

read more
Breakthroughs in the Lab – Blind Spots in Reality 

Breakthroughs in the Lab – Blind Spots in Reality 

Obesity care is at a turning point. GLP-1s like Ozempic and Mounjaro have upended weight loss culture – and the research backs them up. For the first time, multiple randomized trials have found that anti-obesity medications can lead to an average 15-20% weight loss....

read more
Raising Expectations for Medical Liaisons

Raising Expectations for Medical Liaisons

In the last decade, the Medical Science Liaison role has evolved from a scientific messenger to a field based strategist operating in one of the most highly scrutinized environments in healthcare. That evolution is why board certification is moving from optional...

read more